UBS Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

UBS Group’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.44M	Buy	39,680 +870	+2%	+$76.2K	﹤0.01%	4451
2025 Q4	$3.29M	Buy	38,810 +5,063	+15%	+$404K	﹤0.01%	4463
2025 Q3	$2.45M	Sell	33,747 -7,659	-18%	-$528K	﹤0.01%	4769
2025 Q2	$2.71M	Buy	41,406 +4,740	+13%	+$309K	﹤0.01%	4499
2025 Q1	$2.59M	Buy	36,666 +965	+3%	+$67.1K	﹤0.01%	4472
2024 Q4	$2.35M	Sell	35,701 -1,163	-3%	-$80K	﹤0.01%	4575
2024 Q3	$2.6M	Buy	36,864 +501	+1%	+$34.9K	﹤0.01%	3742
2024 Q2	$2.41M	Sell	36,363 -1,997	-5%	-$131K	﹤0.01%	3576
2024 Q1	$2.6M	Sell	38,360 -4,837	-11%	-$320K	﹤0.01%	3672
2023 Q4	$2.67M	Sell	43,197 -1,023	-2%	-$60.1K	﹤0.01%	3505
2023 Q3	$2.61M	Sell	44,220 -1,068	-2%	-$65.5K	﹤0.01%	3187
2023 Q2	$2.7M	Sell	45,288 -45,246	-50%	-$2.69M	﹤0.01%	3236
2023 Q1	$5.29M	Sell	90,534 -1,446	-2%	-$87.1K	﹤0.01%	2461
2022 Q4	$5.71M	Buy	91,980 +10,293	+13%	+$619K	﹤0.01%	2373
2022 Q3	$4.62M	Buy	81,687 +39,900	+95%	+$2.46M	﹤0.01%	2428
2022 Q2	$2.67M	Buy	41,787 +13,101	+46%	+$832K	﹤0.01%	2902
2022 Q1	$1.86M	Sell	28,686 -2,115	-7%	-$134K	﹤0.01%	3499
2021 Q4	$2.05M	Sell	30,801 -1,710	-5%	-$108K	﹤0.01%	3714
2021 Q3	$1.99M	Sell	32,511 -34,824	-52%	-$2.21M	﹤0.01%	3582
2021 Q2	$4.17M	Buy	67,335 +34,173	+103%	+$2.08M	﹤0.01%	2882
2021 Q1	$1.96M	Sell	33,162 -4,032	-11%	-$243K	﹤0.01%	3580
2020 Q4	$2.23M	Buy	37,194 +3,195	+9%	+$182K	﹤0.01%	3315
2020 Q3	$1.85M	Buy	33,999 +30	+0.1%	+$1.62K	﹤0.01%	3115
2020 Q2	$1.74M	Buy	33,969 +783	+2%	+$39.4K	﹤0.01%	3001
2020 Q1	$1.49M	Buy	33,186 +3,486	+12%	+$176K	﹤0.01%	3033
2019 Q4	$1.58M	Buy	29,700 +2,178	+8%	+$107K	﹤0.01%	3779
2019 Q3	$1.28M	Sell	27,522 -3,474	-11%	-$166K	﹤0.01%	3737
2019 Q2	$1.56M	Sell	30,996 -7,545	-20%	-$373K	﹤0.01%	3375
2019 Q1	$1.98M	Sell	38,541 -2,103	-5%	-$105K	﹤0.01%	3001
2018 Q4	$1.91M	Buy	40,644 +1,344	+3%	+$68.9K	﹤0.01%	3078
2018 Q3	$2.2M	Sell	39,300 -732	-2%	-$40K	﹤0.01%	3134
2018 Q2	$2.02M	Sell	40,032 -56,289	-58%	-$2.79M	﹤0.01%	3159
2018 Q1	$4.74M	Buy	96,321 +47,121	+96%	+$2.42M	﹤0.01%	2366
2017 Q4	$2.53M	Sell	49,200 -13,836	-22%	-$711K	﹤0.01%	2988
2017 Q3	$3.29M	Sell	63,036 -381	-0.6%	-$19.6K	﹤0.01%	2619
2017 Q2	$3.28M	Sell	63,417 -5,211	-8%	-$263K	﹤0.01%	2525
2017 Q1	$3.45M	Sell	68,628 -12,039	-15%	-$596K	﹤0.01%	2422
2016 Q4	$3.8M	Buy	80,667 +35,280	+78%	+$1.67M	﹤0.01%	2335
2016 Q3	$2.26M	Sell	45,387 -7,629	-14%	-$387K	﹤0.01%	2727
2016 Q2	$2.55M	Sell	53,016 -25,272	-32%	-$1.2M	﹤0.01%	2572
2016 Q1	$3.58M	Sell	78,288 -134,298	-63%	-$6.28M	﹤0.01%	2160
2015 Q4	$11.5M	Buy	212,586 +73,401	+53%	+$3.86M	0.01%	1306
2015 Q3	$6.87M	Sell	139,185 -15,351	-10%	-$880K	﹤0.01%	1661
2015 Q2	$9.01M	Sell	154,536 -22,968	-13%	-$1.34M	0.01%	1558
2015 Q1	$10.2M	Buy	177,504 +50,217	+39%	+$2.75M	0.01%	1462
2014 Q4	$6.42M	Buy	+127,287	New	+$6.2M	﹤0.01%	1868

Other funds holding IHE

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

FIA

Foundations Investment Advisors Phoenix, Arizona $8.07B AUM 24.97% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return

MSCM

McElhenny Sheffield Capital Management Dallas, Texas $403M AUM 28.73% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

UBS Group's IHE Position: Q1 2026 in Review

UBS Group increased its iShares US Pharmaceuticals ETF (IHE) stake by 2.2% in Q1 2026, buying an estimated $76.2K and bringing the position to 39,680 shares worth $3.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4451.

UBS Group first reported a position in IHE in Q4 2014 and has held it in 46 quarters since. The position peaked at $11.5M in Q4 2015. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

UBS Group held 39,680 shares of iShares US Pharmaceuticals ETF worth $3.44M as of Q1 2026.
UBS Group bought 870 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $76.2K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4451 holding.
UBS Group first reported a position in iShares US Pharmaceuticals ETF in Q4 2014 and has held it in 46 quarters since.
UBS Group's iShares US Pharmaceuticals ETF position peaked at $11.5M in Q4 2015.
194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.